Meeder Asset Management Inc Deciphera Pharmaceuticals, Inc. Transaction History

Meeder Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$6.87 - $11.11 $1,106 - $1,788	-161 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$7.7 - $37.13 $1,239 - $5,977	161 New	161 $1,000
Q2 2021 Aug 09, 2021	SELL	$32.73 - $47.95 $83,494 - $122,320	-2,551 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$40.39 - $56.73 $103,034 - $144,718	2,551 New	2,551 $117,000
Q4 2020 Feb 09, 2021	SELL	$51.77 - $66.18 $59,639 - $76,239	-1,152 Closed	0 $0
Q3 2020 Nov 02, 2020	SELL	$43.8 - $58.16 $12,439 - $16,517	-284 Reduced 19.78%	1,152 $58,000
Q2 2020 Aug 11, 2020	BUY	$37.05 - $65.03 $29,788 - $52,284	804 Added 127.22%	1,436 $86,000
Q1 2020 May 15, 2020	SELL	$33.63 - $69.4 $54,816 - $113,122	-1,630 Reduced 72.06%	632 $26,000
Q4 2019 Feb 13, 2020	BUY	$31.7 - $69.93 $66,823 - $147,412	2,108 Added 1368.83%	2,262 $141,000
Q3 2019 Oct 17, 2019	BUY	$19.95 - $38.85 $3,072 - $5,982	154 New	154 $5,000
Q3 2018 Nov 02, 2018	SELL	$33.57 - $42.1 $1,174 - $1,473	-35 Closed	0 $0
Q2 2018 Jul 24, 2018	SELL	$20.06 - $44.95 $60 - $134	-3 Reduced 7.89%	35 $0
Q1 2018 May 03, 2018	BUY	$20.04 - $29.71 $761 - $1,128	38 New	38 $1,000

293K

500

Ticker DCPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,822,100
Description
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.